Evidence map›Paper›PMID 31302306›Full record

ArticleClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2020

Hormone Therapy for Cancer Is a Risk Factor for Relapse of Inflammatory Bowel Diseases.

Jordan E Axelrad, Ahmad Bazarbashi, James Zhou, Daniel Castañeda, Amandeep Gujral, Dylan Sperling, Jason Glass, Manasi Agrawal, Simon Hong, Garrett Lawlor and 9 more

Open access · greenAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 25 citations in OpenAlex.

  1. Inflammatory bowel disease and breast cancer: epidemiological evidence, shared biology, and clinical management.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. The Emerging Roles of π Subunit-Containing GABAInternational journal of medical sciences · 2021
    Review
  9. Sex-based differences in inflammatory bowel diseases: a review.Therapeutic advances in gastroenterology · 2020
    Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 11 institutions in 1 country.

Jordan E AxelradInflammatory Bowel Disease Center at New York University Langone Health, Division of Gastroenterology, Department of Medicine, New York University School of Medicine, New York, New York. Electronic address: Jordan.Axelrad@nyulangone.org.
Ahmad BazarbashiDivision of Gastroenterology, Brigham and Women's Hospital, Boston, Massachusetts.
James ZhouDepartment of Medicine, New York University School of Medicine, New York, New York.
Daniel CastañedaDivision of Gastroenterology and Hepatology, Department of Medicine, Cleveland Clinic Florida, Weston, Florida.
Amandeep GujralCrohn's and Colitis Center at Massachusetts General Hospital, Division of Gastroenterology, Department of Medicine, Harvard Medical School, Boston, Massachusetts.
Dylan SperlingDivision of Cancer Prevention and Control, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
Jason GlassDivision of Gastroenterology, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
Manasi AgrawalDivision of Gastroenterology, Department of Medicine, Lenox Hill Hospital, New York, New York.
Simon HongDivision of Gastroenterology, Department of Medicine, Montefiore Medical Center, New York, New York.
Garrett LawlorDivision of Digestive and Liver Diseases, Department of Medicine, Columbia University Medical Center, New York, New York.
David HudesmanInflammatory Bowel Disease Center at New York University Langone Health, Division of Gastroenterology, Department of Medicine, New York University School of Medicine, New York, New York.
Shannon ChangInflammatory Bowel Disease Center at New York University Langone Health, Division of Gastroenterology, Department of Medicine, New York University School of Medicine, New York, New York.
Shailja ShahDivision of Gastroenterology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Vijay YajnikCrohn's and Colitis Center at Massachusetts General Hospital, Division of Gastroenterology, Department of Medicine, Harvard Medical School, Boston, Massachusetts.
Ashwin AnanthakrishnanCrohn's and Colitis Center at Massachusetts General Hospital, Division of Gastroenterology, Department of Medicine, Harvard Medical School, Boston, Massachusetts.
Hamed KhaliliCrohn's and Colitis Center at Massachusetts General Hospital, Division of Gastroenterology, Department of Medicine, Harvard Medical School, Boston, Massachusetts.
Jean-Frederic ColombelDivision of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
Steven ItzkowitzDivision of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
New York Crohn’s and Colitis Organization
Harvard University · USIcahn School of Medicine at Mount Sinai · USNew York University · USBrigham and Women's Hospital · USCleveland Clinic Florida · USColumbia University Irving Medical Center · USLenox Hill Hospital · USMontefiore Medical Center · USNYU Langone Health · USThe University of Texas Southwestern Medical Center · USVanderbilt University Medical Center · US

Funding

Learning Health System Scholar Program at VanderbiltK12HS026395 · AHRQ · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ROTHMAN, RUSSELL L., ROUMIE, CHRISTIANNE L. · 2018 to 2022
$2.7M
AHRQ HHS K12 HS026395
6 · The paper itself

Abstract

BACKGROUND &

aimsExposure to hormone contraception has been associated with an increased risk of relapse of inflammatory bowel diseases (IBDs). Little is known about the effects of cancer therapies, specifically hormone therapies, on the course of IBD.

methodsWe conducted a retrospective cohort study, collecting data from 5 medical centers, on patients with IBD who received a subsequent diagnosis of breast or prostate cancer from 1997 through 2018. For patients with quiescent IBD at their cancer diagnosis, the primary outcome was relapse of IBD. For patients with active IBD at their cancer diagnosis, the primary outcome was IBD remission.

resultsOur analysis included 447 patients with IBD (44% with Crohn's disease, 53% with ulcerative colitis, and 3% with IBD unclassified) who had either breast (78%) or prostate (22%) cancer. At their cancer diagnosis, 400 patients (90%) had inactive IBD, and 47 (10%) had active IBD. Among patients with inactive IBD, 112 (28%) developed active IBD. Previous exposure to steroids, immunomodulators, or biologics was associated with IBD relapse after a cancer diagnosis (hazard ratio [HR] for steroids, 1.79; 95% CI, 1.18-2.71; HR for immunomodulators, 2.22; 95% CI, 1.38-3.55; HR for biologics, 1.95; 95% CI, 1.01-5.36). Hormone monotherapy (HR, 2.00; 95% CI, 1.21-3.29) and combination cytotoxic and hormone therapy (HR, 1.86; 95% CI, 1.01-3.43) was associated with IBD relapse. Among 34 patients who received only cytotoxic chemotherapy, 75% remained in remission from IBD at 250 months compared with 42% of those who received hormone monotherapy (log rank, 0.02). Among patients with active IBD at their cancer diagnosis, 14 (30%) entered remission from IBD, but there were no significant factors of achieving IBD remission.

conclusionsIn a multicenter retrospective study, we found that patients with IBD and breast or prostate cancer who receive hormone therapy have an increased risk for relapse of IBD and related adverse outcomes.

Indexed as

Colitis, UlcerativeInflammatory Bowel DiseasesHormonesHumansMaleNeoplasm Recurrence, LocalRetrospective StudiesRisk FactorsHormonesCDdisease flarelong-term outcomeUC

Identifiers

PMID31302306
PMCPMC7354097
OpenAlexW2961910500

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.